Leadership of AAVnerGene

Daozhan.jpg

Daozhan Yu, Ph.D

Co-Founder, Chief Executive Officer, and Chairman of the Board

Qizhao.png

Qizhao Wang, Ph.D

Co-Founder, Chief Technology Officer

AAV related publication and Patents

  1. Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.2020

  2. Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII.2020

  3. Mouse gamma-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells. 2020

  4. AKT-dependent and -independent pathways mediate PTEN deletion-induced CNS axon regeneration.2019

  5. A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors. 2017

  6. Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors. 2017

  7. Neuroprotection by eIF2α-CHOP inhibition and XBP-1 activation in EAE/optic neuritiss.2017.

  8. High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction. 2016

  9. Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment. 2016.

  10. Rescue of Glaucomatous Neurodegeneration by Differentially Modulating Neuronal Endoplasmic Reticulum Stress Molecules.2016

  11. Super-resolution imaging of nuclear import of adeno-associated virus in live cells. 2016

  12. Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII Delivery.2014

  13. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus. U.S 10,801,042 

  14. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus.US-10557149-B1